



**BioPharma** 

## Comprehensive genomic profiling assays for oncological studies

## PanCancerIQ™: enhancing precision oncology

sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples. It supports the identification of all relevant DNA and RNA variants implicated in various solid tumor types, along with biomarker content aligned with key guidelines and clinical trials.

PanCancerIQ™ is a next-generation






By identifying genomic alterations driving cancer growth, mutations, insertions and deletions and other key measures for immuno-oncology, along with identifying oncogenic driver events to predict treatment response and resistance, PanCancerIQ advances the future of precision oncology throughout the preclinical and clinical stages. A complete genomic sequencing solution

biomarkers.

PanCancerIQ services include:




patients based on therapeutic response and resistance mechanisms, link multiple data sets to clinical endpoints and identify potential predictive



De novo assay development

Other complementary services that can aid in accelerating the

development of precision oncology therapeutics include:



## Conclusion: in support of oncology clinical trial testing

Supporting biomarker discovery for drug response and resistance studies

- Screening of patients for recruitment in genomically informed trials

Monitoring tumor molecular evolution in recurrence or metastasis







Viracor **BioPharma**